Articles published by Axcella Therapeutics
![](https://mms.businesswire.com/media/20230914273546/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
Axcella Announces Reverse Stock Split Effective September 19, 2023
September 14, 2023
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://mms.businesswire.com/media/20230829372113/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
Axcella Granted Patent for Long COVID Fatigue Treatment
August 29, 2023
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://mms.businesswire.com/media/20230803884578/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
![](https://mms.businesswire.com/media/20230504006005/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
![](https://mms.businesswire.com/media/20230417005358/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
April 17, 2023
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://mms.businesswire.com/media/20230330005233/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 30, 2023
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://mms.businesswire.com/media/20230215005787/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
February 15, 2023
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://mms.businesswire.com/media/20230209005760/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference
February 09, 2023
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://mms.businesswire.com/media/20230123005745/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
January 23, 2023
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Axcella Announces Program Reprioritization and Corporate Restructuring
December 14, 2022
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
November 03, 2022
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022
October 27, 2022
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
October 14, 2022
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)
September 29, 2022
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
September 12, 2022
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20220802005461/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
August 02, 2022
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 19, 2022
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20220330005062/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
![](https://mms.businesswire.com/media/20220323005228/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022
March 23, 2022
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://mms.businesswire.com/media/20220315006352/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
![](https://mms.businesswire.com/media/20220211005373/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
![](https://mms.businesswire.com/media/20220209005826/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference
February 10, 2022
From Axcella Therapeutics
Via Business Wire
Tickers
AXLA
![](https://mms.businesswire.com/media/20220204005326/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
![](https://mms.businesswire.com/media/20220105005992/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
![](https://mms.businesswire.com/media/20220103005465/en/1238469/5/Axcella_Therapeutics_Logo_Color_Registration.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.